CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income	$ 1,602.0	$ 1,999.9	$ 1,449.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	114.9	104.3	96.9
Amortization	294.0	269.3	277.2
Deferred income taxes	(33.4)	(272.3)	(246.6)
Impairment charges	48.9	133.2	105.4
Change in value of contingent consideration	(7.9)	48.7	171.1
Net (gain) loss on sale of investments	(83.5)	5.4	7.0
Share-based compensation expense	576.6	447.6	325.8
Share-based employee benefit plan expense	35.1	40.7	32.6
Derivative instruments	(31.4)	(71.9)	(8.7)
Other, net	18.8	(13.5)	11.0
Change in current assets and liabilities, excluding the effect of acquisitions:
Accounts receivable	(304.7)	(166.3)	(101.4)
Inventory	(50.6)	(56.5)	(89.7)
Other operating assets	(326.2)	52.6	(90.9)
Accounts payable and other operating liabilities	533.0	252.3	287.2
Payment of contingent consideration	0.0	(14.3)	(75.0)
Income tax payable	61.2	39.1	57.4
Deferred revenue	37.1	8.0	16.7
Net cash provided by operating activities	2,483.9	2,806.3	2,225.9
Cash flows from investing activities:
Proceeds from sales of marketable securities available for sale	3,799.6	2,175.9	3,642.3
Purchases of marketable securities available for sale	(1,889.3)	(2,661.4)	(3,983.6)
Payments for acquisition of businesses, net of cash acquired	(7,695.1)	(710.0)	0.0
Capital expenditures	(286.3)	(150.3)	(119.7)
Proceeds from sales of investment securities	92.0	0.0	0.0
Purchases of investment securities	(272.5)	(67.4)	(47.1)
Other investing activities	(7.4)	(24.8)	(20.5)
Net cash used in investing activities	(6,259.0)	(1,438.0)	(528.6)
Cash flows from financing activities:
Payment for treasury shares	(3,256.8)	(2,975.1)	(2,764.6)
Proceeds from short-term borrowing	6,111.5	2,566.9	4,462.0
Principal repayments on short-term borrowing	(6,213.2)	(3,012.2)	(4,227.9)
Proceeds from the issuance of long-term debt, net of issuance costs	7,913.3	2,470.6	1,479.6
Repayments of long-term debt	(513.9)	0.0	0.0
Net (payments) proceeds from common equity put options	(8.6)	10.3	1.2
Payment of contingent consideration	0.0	(25.7)	(225.0)
Net proceeds from share-based compensation arrangements	251.7	297.2	551.6
Excess tax benefit from share-based compensation arrangements	300.5	250.6	169.4
Net cash provided by (used in) financing activities	4,584.5	(417.4)	(553.7)
Effect of currency rate changes on cash and cash equivalents	(50.7)	(63.7)	0.4
Net increase in cash and cash equivalents	758.7	887.2	1,144.0
Cash and cash equivalents at beginning of period	4,121.6	3,234.4	2,090.4
Cash and cash equivalents at end of period	4,880.3	4,121.6	3,234.4
Supplemental schedule of non-cash investing and financing activity:
Fair value of contingent consideration issued in business combinations	166.0	1,060.0	0.0
Change in net unrealized (gain) loss on marketable securities available for sale	314.4	(494.0)	(205.1)
Investment in NantBioScience, Inc. preferred equity	0.0	90.0	0.0
Supplemental disclosure of cash flow information:
Interest paid	243.3	196.2	90.8
Income taxes paid	$ 361.1	$ 294.6	$ 291.9